癌症患者在高危和低危性腺毒性化疗前卵母细胞冷冻保存的活产率与成本效益建模
本研究使用决策分析模型,基于治疗性腺毒性估算25-40岁癌症患者在接受卵母细胞冷冻保存(FP-OC)与期待管理后的活产率(LBR)和成本效益。结果显示,FP-OC较未行FP-OC提高各年龄段接受低危化疗(LRC)或高危化疗(HRC)女性的活产率,但成本始终更高;对高龄接受LRC或年轻接受HRC的女性最具成本效益。使用供卵IVF可作为自体FP-OC的成功替代方案。
要点
- FP-OC较未行FP-OC提高各年龄段接受LRC或HRC女性的活产率,但成本始终更高。
- FP-OC对高龄接受LRC或年轻接受HRC的女性最具成本效益。
- 使用供卵IVF可作为自体FP-OC的成功替代方案。
核心结论
- 癌症治疗前卵母细胞冷冻保存比不进行卵母细胞冷冻保存成本更高但更有效(产生更多活产),对接受高危化疗的患者最有益。
研究设计与样本
- 本研究使用决策分析模型估算癌症患者生育力保存的有效性和成本。
- 基于年龄的活产率和每活产成本针对25-40岁年龄计算,基于治疗性腺毒性。
- 决策分析模型使用Treeage Pro 2015构建,病例基础概率来源于国家登记处、实践指南和全国不孕症实践网络(IntegraMed)的医疗记录。
主要发现
- 与未行FP-OC相比,FP-OC提高了所有年龄接受低危化疗或高危化疗女性的活产率。
- FP-OC对高龄接受低危化疗或年轻接受高危化疗的女性最具成本效益。
- 尽管FP-OC导致更高的活产率,但始终成本更高。
- 使用供卵IVF可作为自体FP-OC的成功替代方案。
临床怎么用
- 该分析模型有助于指导从业者为25至40岁考虑在癌症诊断时进行FP-OC的女性提供咨询。
- 模型提供了从诊断到活产的现实路径,并考虑了大多数成本和结局可能性。
局限性
- 决策树结果反映某些事件的概率,汇编自多个 reputable 来源,但并非直接来自招募的患者队列。
- 结局基于美国估算,应在个体患者诊断、治疗护理计划和原籍国的更广泛背景下解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the live-birth rate (LBR) and cost-effectiveness of fertility preservation with oocyte cryopreservation (FP-OC) compared to expectant management in cancer patients age 25-40 based on estimated gonadotoxicity of treatments 5 years after cancer diagnosis? SUMMARY ANSWER: Oocyte cryopreservation prior to cancer treatment is more costly, yet more effective (producing more live births), than not undergoing oocyte cryopreservation but it is most beneficial for patients undergoing high-risk chemotherapy (HRC). WHAT IS KNOWN ALREADY: The decision to undergo FP prior to treatment is multifactorial and can be costly and delay treatment. Not all treatments carry the same gonadotoxicity and patients may choose to undergo FP-OC based on the probability of premature ovarian insufficiency, predicted outcomes and cost. A comprehensive model that incorporates age at diagnosis and toxicity of treatment to help guide patients in the decision to undergo FP-OC does not yet exist. STUDY DESIGN, SIZE DURATION: This study used a Decision Analysis Model to estimate effectiveness and cost of FP for cancer patients. PARTICIPANTS/MATERIALS, SETTING, METHODS: Age-based estimates of LBR and cost per live birth were calculated for ages 25-40 years based on gonadotoxicity of treatment. A decision analysis model was constructed using Treeage Pro 2015 with case base probabilities derived from national registries, practice guidelines and medical records from a national network of infertility practices (IntegraMed). MAIN RESULTS AND THE ROLE OF CHANCE: Compared to no FP-OC, FP-OC improved LBRs for women of all ages undergoing either low-risk chemotherapy (LRC) or HRC; however, it was most cost effective for women undergoing LRC at older ages or HRC at younger ages. Although FP-OC results in higher LBRs, it was always more costly. Using donor oocyte IVF can be a successful alternative to autologous FP-OC. LIMITATIONS REASONS FOR CAUTION: Decision tree results reflect probabilities of certain events and are compiled from multiple reputable sources but are not directly derived from a recruited cohort of patients. Outcomes are based on United States estimates and should be interpreted in the broader context of individual patient diagnoses, treatment care plans and country of origin. WIDER IMPLICATIONS OF THE FINDINGS: The development of this analytic model will help guide practitioners in their counseling of women from age 25 to 40 years, who are considering FP-OC at the time of cancer diagnosis. It provides a realistic pathway from diagnosis to LB and accounts for the majority of costs and outcome possibilities. STUDY FUNDING/COMPETING INTEREST(S): This study was partially funded by a grant from National Institute of Health (NIH)/National Institute of Child Health and Human Development (NICHD) (R01 HD67683) to A.Z.S. There are no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.
引用
- Lyttle Schumacher B, Grover N, Mesen T, et al. Modeling of live-birth rates and cost-effectiveness of oocyte cryopreservation for cancer patients prior to high- and low-risk gonadotoxic chemotherapy. Hum Reprod. 2017. PMID: 28938728. doi:10.1093/humrep/dex257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。